B G Durie

Summary

Affiliation: St. Vincent's Comprehensive Cancer Center
Country: USA

Publications

  1. ncbi request reprint RT-PCR amplicons in the plasma of multiple myeloma patients--clinical relevance and molecular pathology
    B G Durie
    Cedars Sinai Comprehensive Cancer Center, Division of Hematology Oncology, Los Angeles, CA 90048, USA
    Acta Oncol 39:789-96. 2000
  2. ncbi request reprint Magnitude of response with myeloma frontline therapy does not predict outcome: importance of time to progression in southwest oncology group chemotherapy trials
    Brian G M Durie
    Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    J Clin Oncol 22:1857-63. 2004
  3. ncbi request reprint Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation
    Brian G M Durie
    Cedars Sinai Comprehensive Cancer Center, Los Angeles, CA, USA
    Hematol J 4:379-98. 2003
  4. ncbi request reprint Whole-body (18)F-FDG PET identifies high-risk myeloma
    Brian G M Durie
    Division of Hematology Oncology, Department of Medicine, Cedars Sinai Comprehensive Cancer Center, Cedars Sinai Medical Center, Los Angeles, California, USA
    J Nucl Med 43:1457-63. 2002
  5. ncbi request reprint The epidemiology of multiple myeloma
    B G Durie
    Hematology/Oncology Division, Cedars-Sinai Medical Center, Cedars-Sinai Comprehensive Cancer Center, Los Angeles, CA 90048, USA
    Semin Hematol 38:1-5. 2001
  6. ncbi request reprint Treatment of myeloma--are we making progress?
    Brian G M Durie
    N Engl J Med 359:964-6. 2008
  7. doi request reprint Confirmation of the utility of the International Staging System and identification of a unique pattern of disease in Brazilian patients with multiple myeloma
    Vania T M Hungria
    Haematologica 93:791-2. 2008
  8. ncbi request reprint New approaches to treatment for multiple myeloma: durable remission and quality of life as primary goals
    Brian G M Durie
    Department of Medicine, Division of Hematology Oncology, Cedars Sinai Outpatient Cancer Center, Los Angeles, CA 90048 1804, USA
    Clin Lymphoma Myeloma 6:181-90. 2005
  9. ncbi request reprint Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma
    Sundar Jagannath
    St Vincent s Comprehensive Cancer Center, New York, NY 10011 8202, USA
    Br J Haematol 129:776-83. 2005
  10. ncbi request reprint International staging system for multiple myeloma
    Philip R Greipp
    Mayo Clinic College of Medicine and Eastern Cooperative Oncology Group, Rochester, MN, USA
    J Clin Oncol 23:3412-20. 2005

Collaborators

Detail Information

Publications21

  1. ncbi request reprint RT-PCR amplicons in the plasma of multiple myeloma patients--clinical relevance and molecular pathology
    B G Durie
    Cedars Sinai Comprehensive Cancer Center, Division of Hematology Oncology, Los Angeles, CA 90048, USA
    Acta Oncol 39:789-96. 2000
    ..2% homology with an AluSc consensus sequence. The occurrence of RNA amplicons seemed to serve as accurate surrogate markers for active disease in MM that provide new insights to the molecular pathogenesis of the disease...
  2. ncbi request reprint Magnitude of response with myeloma frontline therapy does not predict outcome: importance of time to progression in southwest oncology group chemotherapy trials
    Brian G M Durie
    Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    J Clin Oncol 22:1857-63. 2004
    ..The purpose was to clarify the predictive value of specific levels of myeloma-associated monoclonal protein reduction and time to first progression using mature data sets...
  3. ncbi request reprint Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation
    Brian G M Durie
    Cedars Sinai Comprehensive Cancer Center, Los Angeles, CA, USA
    Hematol J 4:379-98. 2003
    ..2. Staging and prognostic factors. 3. Frontline therapy. 4. High-dose therapy and transplant. 5. Maintenance therapy. 6. Supportive care and management of specific complications. 7. Novel therapies and new technologies...
  4. ncbi request reprint Whole-body (18)F-FDG PET identifies high-risk myeloma
    Brian G M Durie
    Division of Hematology Oncology, Department of Medicine, Cedars Sinai Comprehensive Cancer Center, Cedars Sinai Medical Center, Los Angeles, California, USA
    J Nucl Med 43:1457-63. 2002
    ..The purpose of this study was to evaluate the clinical utility of whole-body PET with (18)F-FDG in patients with multiple myeloma and related monoclonal diseases...
  5. ncbi request reprint The epidemiology of multiple myeloma
    B G Durie
    Hematology/Oncology Division, Cedars-Sinai Medical Center, Cedars-Sinai Comprehensive Cancer Center, Los Angeles, CA 90048, USA
    Semin Hematol 38:1-5. 2001
    ..Full details of the genetic background in a given patient are required to better understand the disease. Hopefully this information will be available soon, using DNA array and related technologies...
  6. ncbi request reprint Treatment of myeloma--are we making progress?
    Brian G M Durie
    N Engl J Med 359:964-6. 2008
  7. doi request reprint Confirmation of the utility of the International Staging System and identification of a unique pattern of disease in Brazilian patients with multiple myeloma
    Vania T M Hungria
    Haematologica 93:791-2. 2008
  8. ncbi request reprint New approaches to treatment for multiple myeloma: durable remission and quality of life as primary goals
    Brian G M Durie
    Department of Medicine, Division of Hematology Oncology, Cedars Sinai Outpatient Cancer Center, Los Angeles, CA 90048 1804, USA
    Clin Lymphoma Myeloma 6:181-90. 2005
    ..Fortunately, new agents already offer longer-term disease control. The ongoing search for a cure will undoubtedly demand courage and dedication on the part of investigators and patients...
  9. ncbi request reprint Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma
    Sundar Jagannath
    St Vincent s Comprehensive Cancer Center, New York, NY 10011 8202, USA
    Br J Haematol 129:776-83. 2005
    ..Bortezomib alone or in combination with dexamethasone is an effective induction therapy with a high CR and nCR rate and manageable toxicities in previously untreated patients with myeloma...
  10. ncbi request reprint International staging system for multiple myeloma
    Philip R Greipp
    Mayo Clinic College of Medicine and Eastern Cooperative Oncology Group, Rochester, MN, USA
    J Clin Oncol 23:3412-20. 2005
    ..There is a need for a simple, reliable staging system for multiple myeloma that can be applied internationally for patient classification and stratification...
  11. ncbi request reprint A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience
    Joth L Jacobson
    Southwest Oncology Group Statistical Center, Seattle, WA 98101 1468, USA
    Br J Haematol 122:441-50. 2003
    ..Additional evaluation in other MM patient populations is needed to confirm results...
  12. ncbi request reprint Management of multiple myeloma: a systematic review and critical appraisal of published studies
    Ambuj Kumar
    Interdisciplinary Oncology Program of the H Lee Moffitt Cancer and Research Institute, University of South Florida, Tampa, FL 33612, USA
    Lancet Oncol 4:293-304. 2003
    ..We conclude that the quality of total evidence supporting treatment recommendations in myeloma is modest at best and has an ample scope for improvement...
  13. doi request reprint Eliminating the complete response penalty from myeloma response criteria
    S Vincent Rajkumar
    Blood 111:5759-60. 2008
  14. doi request reprint Oncology nurses take the lead in providing novel therapy guidelines for multiple myeloma
    Brian G M Durie
    Clin J Oncol Nurs 12:7-8. 2008
  15. doi request reprint Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group
    Heinz Ludwig
    Department of Medicine, Wilhelminenspital, Montleartstr 37, 1160 Vienna, Austria
    Blood 111:4039-47. 2008
    ....
  16. ncbi request reprint Use of bisphosphonates in multiple myeloma: IMWG response to Mayo Clinic consensus statement
    Brian G M Durie
    Mayo Clin Proc 82:516-7; author reply 517-8. 2007
  17. ncbi request reprint Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis
    Jeffrey A Zonder
    Blood 108:403; author reply 404. 2006
  18. ncbi request reprint The role of anatomic and functional staging in myeloma: description of Durie/Salmon plus staging system
    Brian G M Durie
    Cedars Sinai Outpatient Cancer Center at the Samuel Oschin Comprehensive Cancer Institute, Division of Hematology Oncology, Department of Medicine, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Eur J Cancer 42:1539-43. 2006
    ..Wider use of newer imaging will undoubtedly enhance analysis of new trials incorporating novel agents...
  19. ncbi request reprint Osteonecrosis of the jaw and bisphosphonates
    Brian G M Durie
    N Engl J Med 353:99-102; discussion 99-102. 2005
  20. ncbi request reprint Low-dose thalidomide in myeloma: efficacy and biologic significance
    Brian G M Durie
    Cedars Sinai Comprehensive Cancer Center, Los Angeles, CA, USA
    Semin Oncol 29:34-8. 2002
    ..The median effective dose of thalidomide was 200 mg/d. Thalidomide's mechanism of action, particularly its effects on macrophages, is described. Current approaches to single-agent and combination therapy are presented...
  21. doi request reprint Myeloma therapy: 25 years forward--immune modulation then and now
    Brian G M Durie
    Cedars Sinai Outpatient Cancer Center at the Samuel Oschin Comprehensive Cancer Institute, Hematology Oncology and Aptium Oncology, Los Angeles, CA, USA
    J Clin Oncol 26:4698-700. 2008